Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. MELK Is Upregulated in Advanced ccRCC and Promotes Disease Progression by Phosphorylating PRAS40
  2. RCC Lung Metastases Treated by RFA Integrated With Systemic Treatments
  3. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non–Clear Cell RCC
  4. UPLC-MS–Based Urine Untargeted Metabolomic Analyses to Differentiate Bladder Cancer From RCC
  5. Improved Response and Survival With VEGFR-TKIs Following IO Discontinuation in mRCC
  6. Everolimus Exposure as a Predictor of Toxicity in RCC Patients in the Adjuvant Setting
  7. Tivozanib vs Sorafenib in Patients With Advanced Renal Cell Carcinoma
  8. GPI-80 as a Useful Index for Myeloid Cell Heterogeneity and a Potential Prognostic Biomarker for mRCC
  9. New Immunotherapy in the Treatment of Advanced Renal Cancer
  10. Evaluation of Initial Site of Metastasis Improves IMDC Prognostic Prediction in Patients With mRCC

Elsewhere

Recently Updated